Beamr video compression achieves up to 50% improvement for AVs
Keith Goldan, the Chief Financial Officer of Syndax Pharmaceuticals Inc (NASDAQ:SNDX), recently sold a portion of his holdings in the company. According to the latest SEC filing, Goldan sold 3,777 shares of common stock on February 10, 2025, at an average price of $15.504 per share. The transaction was valued at approximately $58,558. Following this sale, Goldan retains ownership of 90,746 shares. The sale occurred near InvestingPro’s Fair Value estimate for the stock, with the company currently maintaining a market capitalization of $1.27 billion. The biotech firm shows strong liquidity with a current ratio of 7.0, and notably holds more cash than debt on its balance sheet.
The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the filing. With the company’s next earnings report scheduled for March 5, 2025, investors can access comprehensive analysis and additional insights through InvestingPro’s detailed research reports, which cover over 1,400 US stocks including SNDX.
In other recent news, Syndax Pharmaceuticals has been the subject of several recent developments. Firstly, Jefferies analyst Kelly Shi reaffirmed a Buy rating on Syndax, maintaining a $43.00 target price. Shi’s outlook for 2025 includes the launch performance of Revuforj with estimated sales of $67 million, and the expected inclusion of NPM1 in the NCCN guidelines.
In a significant organizational change, Syndax has eliminated the role of Chief Medical (TASE:PMCN) Officer (CMO), with Dr. Catherine Madigan departing from her position. The severance compensation details for Dr. Madigan are available in the company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2023.
Syndax’s stock was upgraded to Buy by TD Cowen following the recent approval of the drug Revuforj for the treatment of R/R KMT2Am acute leukemias. H.C. Wainwright also increased its price target for Syndax from $49.00 to $51.00, maintaining a Buy rating after the FDA approval of Revuforj. However, Scotiabank (TSX:BNS) reduced its price target to $18 from $23, maintaining a Sector Perform rating due to concerns about the drug’s approval prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.